Phase 3 trial dashes Oramed’s oral insulin hopes
pharmaphorum
JANUARY 12, 2023
Oramed Pharma has conceded defeat in its attempt to bring an oral formulation of insulin to market for people with type 2 diabetes, after its ORMD-0801 candidate missed the mark in a phase 3 trial. The post Phase 3 trial dashes Oramed’s oral insulin hopes appeared first on.
Let's personalize your content